You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Low-dose hydrocortisone reduces norepinephrine duration in severe burn patients: a randomized clinical trial
|
|---|---|
| Published in |
Critical Care, December 2015
|
| DOI | 10.1186/s13054-015-0740-0 |
| Pubmed ID | |
| Authors |
Fabienne Venet, Jonathan Plassais, Julien Textoris, Marie-Angélique Cazalis, Alexandre Pachot, Marc Bertin-Maghit, Christophe Magnin, Thomas Rimmelé, Guillaume Monneret, Sylvie Tissot |
| Abstract |
IntroductionThe aim of this study was to assess the effect of low-dose corticosteroid therapy in reducing shock duration after severe burn.MethodsA placebo-controlled, double-blind, randomized clinical trial (RCT) was performed on two parallel groups in the burn intensive care unit (ICU). Patients were randomized to receive either low-dose corticosteroid therapy or placebo for seven days. A corticotropin test was performed at the time of randomization, before the administration of the treatment dose. Thirty two severely burned patients with refractory shock (>0.5 ¿g/kg/min of norepinephrine) were prospectively included in the study.ResultsWe included 12 patients in the hydrocortisone-treated group and 15 patients in the placebo group in the final analysis. Among these patients, 21 were nonresponders to the corticotropin test. Median norepinephrine treatment duration (primary objective) was significantly lower in the corticosteroid-treated versus the placebo group (57 hours versus 120 hours, P¿=¿0.035). The number of patients without norepinephrine 72 hours after inclusion was significantly lower in the treated group (P¿=¿0.003, log-rank test analysis). The total quantities of norepinephrine administered to patients were lower in the hydrocortisone-treated versus the placebo group (1,205 ¿g/kg (1,079 to 2,167) versus 1,971 ¿g/kg (1,535 to 3,893), P¿=¿0.067). There was no difference in terms of ICU or hospital length of stay, sepsis incidence, cicatrization or mortality.ConclusionsIn this placebo-controlled, randomized, double-blind clinical trial, we show for the first time that the administration of low-dose hydrocortisone in burn patients with severe shock reduces vasopressor administration.Trial registrationClinicaltrial.gov NCT00149123. Registered 6th September 2005. |
X Demographics
The data shown below were collected from the profiles of 24 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 4 | 17% |
| United States | 2 | 8% |
| Italy | 1 | 4% |
| El Salvador | 1 | 4% |
| Mexico | 1 | 4% |
| Turkey | 1 | 4% |
| France | 1 | 4% |
| Puerto Rico | 1 | 4% |
| Unknown | 12 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 54% |
| Practitioners (doctors, other healthcare professionals) | 8 | 33% |
| Scientists | 2 | 8% |
| Science communicators (journalists, bloggers, editors) | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 2% |
| Unknown | 62 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 11 | 17% |
| Student > Bachelor | 9 | 14% |
| Researcher | 7 | 11% |
| Student > Doctoral Student | 4 | 6% |
| Other | 3 | 5% |
| Other | 8 | 13% |
| Unknown | 21 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 32% |
| Biochemistry, Genetics and Molecular Biology | 4 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Nursing and Health Professions | 3 | 5% |
| Psychology | 3 | 5% |
| Other | 7 | 11% |
| Unknown | 23 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 March 2017.
All research outputs
#2,433,855
of 25,373,627 outputs
Outputs from Critical Care
#2,128
of 6,554 outputs
Outputs of similar age
#39,131
of 395,397 outputs
Outputs of similar age from Critical Care
#167
of 466 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,554 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.8. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 395,397 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 466 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.